{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:42:40Z","timestamp":1790872960622,"version":"4.1.0"},"reference-count":25,"publisher":"Wiley","issue":"8P2","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4186,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2000,8]]},"abstract":"<jats:p>Oxcarbazepine is approved as monotherapy and adjunctive therapy for partial seizures with and without secondarily generalized seizures in adults and as adjunctive therapy for partial\u2010onset seizures in children aged 4\u201316 years. The clinical development of oxcarbazepine is different from the newer antiepileptic drugs (AEDs) in the extent and concordance of results across clinical trials. The safety and efficacy of oxcarbazepine was evaluated in adjunctive therapy trials, in comparative monotherapy trials with classic AEDs in adults and children with newly diagnosed epilepsy, in monotherapy therapeutic failure design trials in patients with refractory partial seizures, and in trigeminal neuralgia and affective disorder. The results of oxcarbazepine in treating epilepsy are discussed.<\/jats:p>","DOI":"10.1592\/phco.20.12.152s.35254","type":"journal-article","created":{"date-parts":[[2004,6,17]],"date-time":"2004-06-17T05:18:27Z","timestamp":1087449507000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Safety and Efficacy of Oxcarbazepine: Results of Randomized, Double\u2010Blind Trials"],"prefix":"10.1002","volume":"20","author":[{"given":"Ahmad","family":"Beydoun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"1","article-title":"Oxcarbazepine: current status and clinical applications","volume":"8","author":"Schacter S.C.","year":"1999","journal-title":"Exp Opin Invest Drugs"},{"key":"e_1_2_1_3_2","volume-title":"Trileptal (oxcarbazepine) package insert","author":"Novartis Pharmaceuticals Corporation","year":"2000"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00609428","article-title":"First dose and steady\u2010state pharmacokinetics of oxcarbazepine and its 10\u2010hydroxy metabolite","volume":"37","author":"Dickinson R.G.","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb05938.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)92602-9"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(94)90787-0"},{"key":"e_1_2_1_8_2","article-title":"Oxcarbazepine placebo\u2010controlled, dose\u2010ranging trial in refractory partial epilepsy","author":"Barcs G.","journal-title":"Epilepsia"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.12.2237"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00024-7"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00025-9"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(96)01013-3"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(89)90070-3"},{"issue":"2","key":"e_1_2_1_14_2","first-page":"A391","article-title":"Safety and efficacy of oxcarbazepine 1200 mg\/day in patients with recent\u2010onset partial epilepsy [abstr]","volume":"52","author":"Sachdeo R.C.","year":"1999","journal-title":"Neurology"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.4.732"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.12.2245"},{"key":"e_1_2_1_17_2","first-page":"A200","article-title":"Safety and efficacy of oxcarbazepine monotherapy [abstr]","volume":"50","author":"Sachdeo R.","year":"1998","journal-title":"Neurology"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1992.tb01772.x"},{"issue":"1","key":"e_1_2_1_19_2","first-page":"70","article-title":"Oxcarbazepine\u2010verapamil drug interaction in healthy volunteers","volume":"32","author":"Kramer G.","year":"1991","journal-title":"Epilepsia"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1992.tb03989.x"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1992.tb04038.x"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1992.tb05051.x"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1992.tb01773.x"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(87)90003-9"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb01792.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1155\/1990\/917164"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.20.12.152S.35254","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.20.12.152S.35254","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:23:53Z","timestamp":1761045833000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.20.12.152S.35254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8]]},"references-count":25,"journal-issue":{"issue":"8P2","published-print":{"date-parts":[[2000,8]]}},"alternative-id":["10.1592\/phco.20.12.152S.35254"],"URL":"https:\/\/doi.org\/10.1592\/phco.20.12.152s.35254","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,8]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}